A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

NCT06830629 · tracked via the Priya Life Science UK tracker

Sponsor

Maze Therapeutics

Phase

Phase 2

Started

2025-02-05

Last updated

2026-07-27

Condition(s) studied

Proteinuric Kidney Disease

Investigational drug(s) / intervention(s)

MZE829

MZE829: Capsules for oral administration

Study summary

The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.

Eligibility

Sex

ALL

Min age

18 Years

Max age

68 Years

Healthy volunteers

Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key Exclusion Criteria: * Organ or bone marrow transplantation * History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer * Conditions that may alter drug absorption, e.g., history of bariatric surgery * Type I diabetes * Pregnant or currently nursing Other inclusion/exclusion criteria defined in protocol apply.

Primary outcome measure(s)

Safety and tolerability as assessed by incidence of adverse events (AEs) — Baseline to Week 12

Trial sites (79)

Facility	City	Region	Status
Research Site	Decatur	Alabama	Recruiting
Research Site	Huntsville	Alabama	Recruiting
Research Site	Montgomery	Alabama	Recruiting
Research Site	Montgomery	Alabama	Recruiting
Research Site	Bloomfield	Connecticut	Recruiting
Research Site	Washington D.C.	District of Columbia	Recruiting
Research Site	Atlantis	Florida	Recruiting
Research Site	Brandon	Florida	Recruiting
Research Site	Hollywood	Florida	Recruiting
Research Site	Melbourne	Florida	Recruiting
Research Site	Orlando	Florida	Recruiting
Research Site	Atlanta	Georgia	Recruiting
Research Site	College Park	Georgia	Recruiting
Research Site	Cordele	Georgia	Recruiting
Research Site	Macon	Georgia	Recruiting
Research Site	Riverdale	Georgia	Recruiting
Research Site	Riverdale	Georgia	Recruiting
Research Site	Savannah	Georgia	Recruiting
Research Site	Snellville	Georgia	Recruiting
Research Site	Chicago	Illinois	Recruiting
Research Site	Chicago	Illinois	Recruiting
Research Site	Evanston	Illinois	Recruiting
Research Site	Kansas City	Kansas	Recruiting
Research Site	Bowling Green	Kentucky	Recruiting
Research Site	Louisville	Kentucky	Recruiting
Research Site	Arnold	Maryland	Recruiting
Research Site	Lutherville	Maryland	Recruiting
Research Site	Oxon Hill	Maryland	Recruiting
Research Site	Dearborn	Michigan	Recruiting
Research Site	Flint	Michigan	Recruiting
Research Site	Pontiac	Michigan	Recruiting
Research Site	Saint Joseph	Michigan	Recruiting
Research Site	Minneapolis	Minnesota	Recruiting
Research Site	Tupelo	Mississippi	Recruiting
Research Site	City of Saint Peters	Missouri	Recruiting
Research Site	St Louis	Missouri	Recruiting
Research Site	Las Vegas	Nevada	Recruiting
Research Site	Jersey City	New Jersey	Recruiting
Research Site	Buffalo	New York	Recruiting
Research Site	Laurelton	New York	Recruiting

+ 39 more sites — see the full list on the official registry below.

Other trials for the same condition

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06830629 on ClinicalTrials.gov ↗ ← All trials in the UK